Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SVRA
#2395
Savara, Inc. - Common Stock
4.7
8
USD
-0.01%
Market Price
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
-1.24%
Monthly Change
-10.32%
6 month change
-21.51%
Year Change
+41.00%
Previous Close
4.8
4
Open
4.8
4
Low
4.7
6
High
5.0
2
Markets
US Stock Market
Healthcare
Biotechnology
SVRA
1D
1W
1M
3M
6M
YTD
1Y
5Y
Open full chart
Financials
Overview
Statement
Statistics
Documents
2004
Current report, Q2 FY2004
2004.04.12
Savara Inc current report, Q2 FY2004
8-K
2003
Current report, Q1 FY2003
2003.02.10
Savara Inc current report, Q1 FY2003
8-K
2002
Current report, Q4 FY2002
2002.10.21
Savara Inc current report, Q4 FY2002
8-K
1
...
41
42
43
44
45
46
47
48
News
JP Morgan Initiates Coverage On Savara with Overweight Rating, Announces Price Target of $12
Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump (NASDAQ:SVRA)
Here's Why You Should Add Savara Stock to Your Portfolio Now
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA)
H.C. Wainwright reiterates Savara stock rating, $10 target
Savara receives FDA priority review for rare lung disease drug
Savara receives FDA day 74 letter for autoimmune PAP drug
Hercules Capital COO Follmann buys $73,400 in HTGC stock
Hercules Capital COO Follmann buys $73,400 in stock
Hercules Capital director Fallon buys $149,800 in shares
Citizens reiterates Savara stock rating on likely FDA approval
FDA accepts Savara’s drug application for rare lung disease